文献速递淋巴瘤

CD19 CAR-T细胞疗法在无淋巴清除条件下治疗寻常型天疱疮的可行性:RESET-PV试验

CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial.
PubMed 文献 · Blood · 2026-01-01

RESET-PV试验报告了前4例未接受淋巴清除预处理即接受全人源CD19 CAR-T(rese-cel)治疗的寻常型天疱疮患者。所有患者天疱疮疾病面积指数评分显著改善,安全性良好,仅1例发生1级细胞因子释放综合征,无神经毒性。初步数据提示淋巴清除预处理在自身免疫病中可能并非必需。

要点

  • 无淋巴清除预处理下,4例PV患者接受rese-cel后疾病面积指数评分均显著改善。
  • 安全性良好:仅1例1级细胞因子释放综合征,无免疫效应细胞相关神经毒性。
  • rese-cel扩增与接受淋巴清除的自身免疫病患者相似,3/4例达B细胞再生障碍。

核心结论

  • 初步数据提示淋巴清除预处理在自身免疫病患者中对于人源化CAR-T疗效可能并非必需。

研究设计与样本

  • RESET-PV试验为DesCAARTes试验的子研究,报告前4例接受无淋巴清除预处理的rese-cel治疗的寻常型天疱疮患者。
  • 试验注册号NCT04422912。

主要发现

  • 输注后所有患者天疱疮疾病面积指数评分显著改善。
  • 仅1例发生1级细胞因子释放综合征,未观察到免疫效应细胞相关神经毒性。
  • PV患者rese-cel扩增与接受淋巴清除的其他自身免疫病患者相似。
  • 所有PV患者出现B细胞耗竭,其中3/4例达B细胞再生障碍。
  • 观察到血清BAFF水平升高,3/4例处于接受淋巴清除的患者范围最低端;2/4例PV自身抗体下降。

临床怎么用

  • 对于自身免疫病患者,可探索无淋巴清除预处理的CD19 CAR-T治疗策略以减少预处理毒性。

局限性

  • 样本量仅4例,为初步数据,需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphodepleting preconditioning (LD) is essential for the efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies. However, in the setting of autoimmune diseases (ADs), the contribution of LD for efficacy is unclear. Here, we report on the early safety, efficacy, and correlative data of the first 4 patients with pemphigus vulgaris (PV) who received resecabtagene autoleucel (rese-cel), a fully human CD19 CAR T-cell therapy, without LD in the RESET-PV trial, a substudy of the DesCAARTes trial. Following infusion, pemphigus disease area index scores improved significantly in all patients. A favorable safety profile was observed, with a single episode of grade 1 cytokine release syndrome. Immune effector cell-associated neurotoxicity was not observed. Rese-cel expansion was similar in patients with PV compared with other rese-cel-treated patients with AD who received LD. B-cell depletion was observed in all patients with PV, with 3 of 4 patients achieving B-cell aplasia. Elevations in serum B-cell activating factor (BAFF) level were observed, with 3 of 4 patients achieving levels within the lowest end of the range exhibited in rese-cel-treated patients with AD who received LD. PV autoantibodies decreased in 2 of 4 patients. These preliminary data suggest that LD may be dispensable for humanized CAR T-cell efficacy in patients with AD. This trial was registered at www.clinicaltrials.gov as NCT04422912.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nunez D, Stadanlick J, Furmanak T, et al. CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial. Blood. 2026. PMID: 42201777. doi:10.1182/blood.2025032093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。